Novartis has rejected overtures from President Donald Trump to expand production jobs in the U.S., reports Swiss media sources.
According to SWI swissinfo, Novartis CEO Joe Jimenez told Swiss media that Trump's work visa restrictions in the U.S. have made Switzerland and Europe a more attractive location for investment.
Jimenez was one of several pharma leaders who met with Trump in January to discuss drug pricing and potentially increasing jobs in the United States.
Novartis employs 13,000 people in Switzerland out of a total 118,000 workers in 155 countries. The drugmaker currently has more than 22,000 employees in the U.S., according to SWI.